SUPPLEMENTARY MATERIAL "Total NT-proBNP, a novel biomarker in atrial fibrillation. A mechanistic analysis of the GISSI-AF trial." Lidia Staszewsky et al. "Appendix 1. Echocardiography, Assays of circulating biomarkers, Detection of recurrent AF during follow-" up Echocardiography Left atrial and ventricular parameters were analysed according to the standards of the American and European “Echocardiography Societies”. Grading of mitral valve regurgitation and information about echocardiographic methods have been described elsewhere (1). "The following variables were collected: maximum left atrial volume index (LAVImax), minimum left atrial" "volume index (LAVImin), left atrial emptying fraction (LAEF), the early transmitral Doppler flow velocity to" "peak early diastolic tissue velocity of the septal mitral annulus ratio (E/e’), left ventricle ejection fraction" (LVEF). Assays of circulating biomarkers Cardiac stress biomarkers N-terminal pro-B type natriuretic peptide (NT-proBNP) is a pro-hormone synthetized by cardiomyocytes in response to: a) increased myocardial wall stress from volume and pressure load (2) and b) myocardial ischemia (3). Total N-terminal pro-B type natriuretic peptide (total NT-proBNP) this new pre-commercial Roche assay is also suitable for detection of glycosylated NT-proBNP. The term “total NT-proBNP” refers to the sum of glycosylated and unglycosylated NT-proBNP. Røsjø et al. (4) examined the influence of glycosylation on the "diagnostic and prognostic accuracy of NT-proBNP in unselected patients with dyspnea, and found higher" NT-proBNP concentrations after removing sugar moieties from NT-proBNP1–76 with deglycosylation "enzymes in plasma from patients presenting dyspnea, particularly those with confirmed heart failure. The" "total NT-proBNP pre-commercial Roche assay overcomes the time-consuming, costly procedures of" enzymatic deglycosylation used by Røsjø et al. Total NT-proBNP/NT-proBNP ratio is a score to detect the amount of unglycosylated NT-proBNP in a patient’s sample (5). A ratio is calculated between the circulating titers of total NT-proBNP and the NT- proBNP. The ratio is particularly suited to assess the role of glycosylation of NT-proBNP. Markers of extracellular matrix "Angiopoietin 2 (Ang 2) is a growth factor glycoprotein involved in angiogenesis, neovascularization," endothelial function and inflammatory processes (6). Expression profiling studies have identified endothelial cells as the primary source of Ang 2. This angiopoietin is a transcriptionally powerfully regulated "cytokine, stored in the Weibel-Palade bodies and can act in an autocrine manner to control endothelial cell" "dynamics. It can be secreted within a few minutes of stimulation, thus active in homeostatic reactions such" as inflammation and coagulation (7). "Fibroblast growth factor 23 (FGF-23) is a hormone involved in phosphorus homeostasis, vitamin D" metabolism and bone mineralization. It is a potential marker of renal function and stimulates the "fibroblasts growth. Although it is still not clear how FGF-23 is associated with AF, its plasma concentration" "has been associated with endothelial dysfunction, vascular calcification and systemic inflammation (8,9)." Insulin-like-growth factor -binding protein-7 (IGFBP 7) is expressed in many normal tissues and highly in "the vasculature, particularly in Weibel-Palade bodies(10). It is involved in several physiological mechanism" "such as cell proliferation, adhesion, senescence, collagen deposition, apoptosis and angiogenesis (11)." "Dickopf-related protein-3 (DKK3) expressed in the endothelium and muscles, is involved in the regulation" of cardiac remodeling and differentiation of stem cells into vascular smooth muscle cells. It antagonizes cardiac hypertrophy by the Wnt signaling pathway (12). Bone morphogenic protein-10 (BMP-10). BMP-10 is a protein coding gene with a role in cardiomyocyte growth in the trabecular and compact myocardium of the right atrium and ventricle (13). Circulating BMP10 has been recently shown to be independently related to AF recurrence after ablation (14). Inflammatory markers "Growth differentiation factor-15 (GDF-15) or macrophage inhibitory cytokine-1 (MIC-1), part of the" "transforming growth factor superfamily, is associated with other inflammatory markers. This marker is not" "cardiac specific, but has been reported to be related to impaired fibrin clot lysability in the left atrium (15)." Myocardial injury markers Myosin binding protein (MyBPC3) is a thick nodular filament protein belonging to the intracellular Ig and fibronectin superfamily. It stabilizes the sarcomere structure and regulates actinomyosin cross-bridging; it is highly expressed in the cardiac muscle of the LV and is promptly released into the circulation after "myocardial injury (16,17)." "Fatty-acid-binding protein 3 (FABP3) - also termed heart-type fatty acid binding protein -, is a member of" "the intracellular lipid-binding protein family involved in fatty acid transport, cell growth, cellular signaling" and gene transcription. FABP3 is highly expressed in cardiac and skeletal muscles and is released rapidly "from the myocardium into the circulation after cardiomyocyte injury (18,19)." Laboratory personnel blinded to clinical information relating to the plasma samples did all the assays in Roche Diagnostics. Detection of recurrent AF during follow-up "Recurrent AF was checked weekly by a trans-telephonic monitoring device (Cardiobios1; Telbios SpA, Milan," "Italy), and during the follow-up visits or symptomatic episodes to the coordinating centre and the attending" physician. Each episode of AF was assessed blindly by a central reader and verified by an ad-hoc committee (20) "Appendix 2. Patients’ baseline clinical, eletrocardiographic and echocardiograpic characteristics." All Patients with AF recurrence Patients without AF recurrence P N=382 N=203 N=179 Sex Female N° (%) 142 (37.2%) 65 (32.0%) 77 (43.0%) "0,026" Age Years Mean+-SD 67.6 +- 9.1 67.3 +- 9.2 67.9 +- 9.0 "0,557" BMI Kg/m2 Mean+-SD 27.9 +- 4.3 27.9 +- 3.9 27.8 +- 4.7 "0,838" Systolic blood pressure mmHg Mean+-SD 138.3 +- 16.5 137.4 +- 16.2 139.2 +- 16.9 "0,290" Diastolic blood pressure mmHg Mean+-SD 81.2 +- 8.4 80.6 +- 8.7 81.8 +- 8.1 "0,154" eGFR mL min-1 1.73m-2 Mean+-SD 76.3 +-25.0 78.1 +- 25.6 74.3 +- 24.3 "0,142" Inclusion criteria >2 episodes in AF Prior 6 months N° (%) 154 (40.8%) 93 (46.3%) 61 (34.7%) "0,022" Cardioversion Prior 2 weeks N° (%) 336 (88.0%) 174 (85.7%) 162 (90.5%) "0,151" Heart failure. LVEF<40% or both N° (%) 42 (11.0%) 25 (12..3%) 17 (9.5%) "0,380" History of hypertension N° (%) 324 (84.8%) 167 (82.3%) 157 (87.7%) "0,139" Diabetes mellitus N° (%) 50 (13.1%) 28 (13.8%) 22 (12.3%) "0,664" History of stroke N° (%) 15 (3.9%) 7 (3.4%) 8 (4.5%) "0,608" Peripheral artery disease N° (%) 22 (5.8%) 15 (7.4%) 7 (3.9%) "0,145" Documented CAD N° (%) 41 (10.7%) 25 (12.3%) 16 (8.9%) "0,287" AF episode with LA dilatation N° (%) 52 (13.6%) 33 (16.3%) 19 (10.6%) "0,109" Comorbidities Peripheral embolism N° (%) 4 (1.0%) 3 (1.5%) 1 (0.6%) "0,378" Renal dysfunction N° (%) 10 (2.6%) 5 (2.5%) 5 (2.8%) "0,840" COPD N° (%) 33 (8.6%) 21 (1.3%) 12 (6.7%) "0,206" Neoplasia N° (%) 12 (3.15%) 4 (2.0%) 8 (4.5%) "0,162" Current smoking N° (%) 36 (9.4%) 20 (9.9%) 16 (8.9%) "0,212" Alcohol abuse N° (%) 4 (1.0%) 1 (0.5%) 3 (1.7%) "0,257" Electrocardiographic findings Heart rate N=381 Mean+-SD 62.2 +- 9.7 61.9 +- 9.8 62.6 +- 9.6 "0,496" QRS > 120 ms N=381 N° (%) 43 (11.3%) 23 (11.4%) 20 (11.2%) "0,948" LVH N=382 N° (%) 34 (8.9%) 19 (9.4%) 15 (8.4%) "0,737" Pathological Q waves N=382 N° (%) 11 (2.9%) 6 (3.0%) 5 (2.8%) "0,925" Echocardiographic variables LAVImax N=283 Mean+-SD 42.6 +- 14.7 43.6 +- 16.0 41.5 +- 13.2 "0,246" LAVImin N=277 Mean+-SD 23.3 +- 12.3 24.5 +- 13.4 22.0 +- 10.8 "0,092" LAEF N=275 Mean+-SD 47.5 +- 13.3 46.6 +- 13.9 48.6 +- 12.5 "0,224" E/e’ N=108 Mean+-SD 12.6 +- 8.6 13.7 +- 11.3 11.5 +- 4.8 "0,191" LVEF N=289 Mean+-SD 60.5 +- 12.3 59.6 +- 13.1 61.6 +- 11.3 "0,171" Concomittant cardiovascular therapies Amiodarone N° (%) 148 (38.7%) 74 (36.5%) 74 (41.3%) "0,328" Sotalol N° (%) 28 (7.3%) 18 (8.9%) 10 (5.6%) "0,220" ACE inhibitors N° (%) 206 (53.9%) 115 (56.7%) 91 (50.8%) "0,255" Beta-blockers N° (%) 114 (29.8%) 58 (28.6%) 56 (31.3%) "0,563" Digitalis N° (%) 16 (4.2%) 10 (4.9%) 6 (3.4%) "0,443" Diuretics N° (%) 16 (4.2%) 10 (4.9%) 6 (3.4%) "0,220" Aldosterone blockers N° (%) 20 (5.2%) 8 (3.9%) 12 (6.7%) "0,226" Statins N° (%) 98 (25.7%) 53 (26.1%) 45 (14.1%) "0,829" Oral anticoagulants N° (%) 233 (61.0%) 126 (62.1%) 107 (59.8%) "0,647" Aspirin N° (%) 101 (26.4%) 55 (27.1%) 46 (25.7%) "0,758" Randomized to Valsartan N° (%) 186 (48.7%) 106 (52.2%) 80 (44.7%) "0,142" "Table contents: modified from Latini et al. JIM 2010 previous author’s authorization. COPD - chronic obstructive pulmonary disease; LVH - left ventricular hypertrofia; LAVImax - left atrial maximal volume index; LAVImin - left atrial minimum volume index; LAEF - left atrial empting fraction; E/e’ - ratio of early transmitral Doppler flow velocity to peak early diastolic tissue velocity of the septal mitral annulus; LVEF - left ventricular ejection fraction." Appendix 3. Descriptive statistics at each study visit (only patients with NT-proBNP measurements at baseline (382). Table 1 Biomarker/vi sit N° Mean Std Dev Median Q1 Q3 Min Max Reference range Total NT BL 376 1727 1712 1230 667 2011 75 12700 "798 (332–2296) pg/mL, median (Q1-Q3)" proBNP 6 M 321 1494 1611 985 507 1959 34 12626 pg/mL 12 M 323 1672 1825 1008 564 2112 62 11992 BL 382 "3,446" "4,963" "1,910" 950 "3,670" 50 4347 "125 pg/mL for age 0-74 years, < 450 pg/mL for age 75-99" NT-proBNP (pg/mL) 6 M 325 "2,786" "4,145" "1,360" 660 "3,240" 50 3906 12 M 331 "3,280" "5,559" "1,490" 630 "3,500" 50 6345 BL 379 344 195 291 221 399 073 "1,504" 3.3 (2.5–5.3) ng/mL Ang2 6 M 324 285 134 249 201 319 101 "1,014" ng/mL 12 M 329 288 131 256 202 328 116 "1,009" median (Q1-Q3) BL 375 209 052 202 175 233 114 504 NA BMP10 6 M 321 205 047 201 175 228 116 476 ng/mL 12 M 327 209 050 200 174 234 115 454 BL 377 "5,987" "1,537" 575 493 687 271 "1,426" "T1<65 ng/mL, T3≥75ng/mL" "DKK3 ng/mL" 6 M 321 "5,783" "1,442" 558 482 640 287 "1,187" 12 M 324 "5,951" "1,647" 575 486 662 268 "1,369" BL 377 223 101 202 165 255 087 917 433.71 ± 298.01 pg/mL ESM1 6 M 321 204 065 194 162 233 097 565 ng/mL 12 M 324 213 070 199 164 247 085 568 BL 375 "3,098" "1,096" 292 242 353 121 "1,053" <5 μg/L FABP3 6 M 321 "3,317" "1,117" 312 257 388 116 867 ng/mL 12 M 327 "3,480" "1,213" 331 262 401 150 914 "FGF23 ng/mL" "BL 6 M 12 M" "374 321 322" "0.14 0.14 0.14" "0.10 0.09 0.10" "0.11 0.11 0.12" "0.09 0.09 0.09" "0.15 0.15 0.15" "0.01 0.01 0.03" "0.87 0.92 0.94" "70 [53 – 99] median (Q1- Q3), relative units (RU)/mL or 44 (range 9- 162) pg/mL" BL 375 1272 793 1053 745 1523 235 7059 762 ( 600-959) median (Q1-Q3) "GDF15 pg/mL" 6 M 321 1344 1136 1080 794 1518 317 12471 12 M 327 1355 965 1140 808 1555 369 9783 BL 379 178 44 172 152 194 97 685 117.8 ng/mL IGFBP7 6 M 324 179 48 170 154 191 80 705 ng/mL 12 M 329 184 49 174 157 199 91 701 BL 373 563 633 369 229 635 034 "4,848" 13.0 ng/mL MYBPC3 6 M 321 486 631 318 198 542 029 "6,673" pg/mL 12 M 327 498 591 310 191 595 0 "4,705" NT-proBNP - N-terminal pro-B type natriuretic peptide; Ang 2 - Angiopoietin 2; BMP10 - Bone morphogenic protein-10;DKK3 - Dickopf-related protein-3; ESM1 - Endothelial cell specific molecule 1; FABP3 - Fatty acid-binding protein 3; FGF23 – Fibroblast Growth Factor 23; GDF15 - Growth differentiation factor-15; IGFBP7 - Insulin-like-growth factor -binding protein-7; MyBPC3 - Myosin binding protein 3. Appendix 4. Concentrations of circulating biomarkers in patients with and without clinical HF or LVEF<40%. Total (382) Heart failure (42) No heart failure (340) P * Median IQR Median IQR Median IQR Total NT-proBNP (pg/mL) baseline 1230 667-2011 1962 1070-4212 1129 647-1913 5.5x10-6 6 months 985 507-1959 1546 563-3289 939 501-1855 "0,014" 12 months 1008 564-2112 1456 704-3352 976 541-2051 "0,075" NT-proBNP (pg/mL) baseline 191 95-367 436 214-851 178 89-316 2.6x10-7 6 months 136 66-324 222 95-730 133 59-302 "0,003" 12 months 149 63-350 296 115-809 140 61-327 "0,004" Total NT-proBNP/ NT-proBNP baseline 623 4.83-8.36 524 3.76-6.22 655 4.97-8.77 3.1x10-5 6 months 675 5.35-9.14 562 4.02-6.88 694 5.55-9.25 "0,001" 12 months 699 4.87-9.61 498 3.65-7.57 718 5.09-9.75 3.9x10-4 Ang2 (ng/mL) baseline 291 2.21-3.99 395 2.91-5.78 277 2.16-3.71 5.6x10-7 6 months 249 2.01-3.19 303 2.36-4.55 247 1.98-3.07 "0,002" 12 months 256 2.02-3.28 285 2.30-4.91 253 1.97-3.22 "0,002" "BMP10 (ng/ml)" baseline 202 1.75-2.33 206 1.82-2.46 202 1.73-2.33 "0,314" 6 months 201 1.75-2.28 200 1.81-2.33 201 1.72-2.28 "0,631" 12 months 200 1.74-2.34 195 1.64-2.26 202 1.77-2.34 "0,348" "MYBPC3 (pg/ml)" baseline 369 2.29-6.35 712 3.82-13.66 340 2.08-5.99 1.0x10-6 6 months 332 1.98-5.51 539 3.22-13.08 318 1.93-5.31 2.0x10-5 12 months 310 1.91-5.95 473 2.41-9.86 301 1.84-5.40 "0,005" * P value for Kruskall-Wallis. NT-proBNP - N-terminal pro-B type natriuretic peptide; Ang 2 - Angiopoietin 2; BMP10 - Bone morphogenic protein-10; MyBPC3 - Myosin binding protein 3. REFERENCES "1. Staszewsky L, Wong M, Masson S, Raimondi E, Gramenzi S, Proietti G, et al. Left atrial remodeling and" response to valsartan in the prevention of recurrent atrial fibrillation: the GISSI-AF echocardiographic substudy. Circ Cardiovasc Imaging. 2011 Nov;4(6):721–8. "2. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998 Jul 30;339(5):321–8." "3. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, et al. Increased cardiac BNP" expression associated with myocardial ischemia. FASEB J. 2003 Jun;17(9):1105–7. "4. Røsjø H, Dahl MB, Jørgensen M, Røysland R, Brynildsen J, Cataliotti A, et al. Influence of glycosylation" on diagnostic and prognostic accuracy of N-terminal pro-B-type natriuretic peptide in acute dyspnea: data from the Akershus Cardiac Examination 2 Study. Clin Chem. 2015 Aug;61(8):1087–97. "5. Takahama H, Takashio S, Nishikimi T, Hayashi T, Nagai-Okatani C, Nakagawa Y, et al. Ratio of pro-B-" "type natriuretic peptide (BNP) to total BNP is decreased in mild, but not severe, acute decompensated heart failure patients: A novel compensatory mechanism for acute heart failure. Int J Cardiol. 2018 01;258:165–71." "6. Freestone B, Chong AY, Lim HS, Blann A, Lip GYH. Angiogenic factors in atrial fibrillation: a possible" role in thrombogenesis? Ann Med. 2005;37(5):365–72. "7. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, et al. The Tie-2 ligand" angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood. 2004 Jun 1;103(11):4150–6. "8. Mathew JS, Sachs MC, Katz R, Patton KK, Heckbert SR, Hoofnagle AN, et al. Fibroblast growth factor-" 23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation. 2014 Jul 22;130(4):298–307. "9. Chua W, Easter CL, Guasch E, Sitch A, Casadei B, Crijns HJGM, et al. Development and external" validation of predictive models for prevalent and recurrent atrial fibrillation: a protocol for the analysis of the CATCH ME combined dataset. BMC Cardiovasc Disord. 2019 21;19(1):120. "10. van Breevoort D, van Agtmaal EL, Dragt BS, Gebbinck JK, Dienava-Verdoold I, Kragt A, et al. Proteomic" screen identifies IGFBP7 as a novel component of endothelial cell-specific Weibel-Palade bodies. Journal of Proteome Research. 2012 May 4;11(5):2925–36. "11. Gandhi PU, Chow SL, Rector TS, Krum H, Gaggin HK, McMurray JJ, et al. Prognostic Value of Insulin-" Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. J Card Fail. 2017 Jan;23(1):20–8. "12. Yu B, Kiechl S, Qi D, Wang X, Song Y, Weger S, et al. A Cytokine-Like Protein Dickkopf-Related Protein 3" Is Atheroprotective. Circulation. 2017 Sep 12;136(11):1022–36. "13. Kahr PC, Piccini I, Fabritz L, Greber B, Schöler H, Scheld HH, et al. Systematic analysis of gene" expression differences between left and right atria in different mouse strains and in human atrial tissue. PLoS ONE. 2011;6(10):e26389. "14. Reyat JS, Chua W, Cardoso VR, Witten A, Kastner PM, Kabir SN, et al. Reduced left atrial" cardiomyocyte PITX2 and elevated circulating BMP10 predict atrial fibrillation after ablation. JCI Insight. 2020 Aug 20;5(16). "15. Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, et al. Growth differentiation" "factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014 Nov 18;130(21):1847–58." "16. Kuster DWD, Cardenas-Ospina A, Miller L, Liebetrau C, Troidl C, Nef HM, et al. Release kinetics of" circulating cardiac myosin binding protein-C following cardiac injury. Am J Physiol Heart Circ Physiol. 2014 Feb 15;306(4):H547-556. "17. Lahm H, Dreßen M, Beck N, Doppler S, Deutsch M-A, Matsushima S, et al. Myosin binding protein H-" like (MYBPHL): a promising biomarker to predict atrial damage. Sci Rep. 2019 10;9(1):9986. "18. Smathers RL, Petersen DR. The human fatty acid-binding protein family: evolutionary divergences and" functions. Hum Genomics. 2011 Mar;5(3):170–91. "19. Shirakabe A, Hata N, Kobayashi N, Okazaki H, Matsushita M, Shibata Y, et al. Worsening renal failure" in patients with acute heart failure: the importance of cardiac biomarkers. ESC Heart Fail. 2019 Apr;6(2):416–27. "20. Disertori M, Latini R, Maggioni AP, Delise P, Di Pasquale G, Franzosi MG, et al. Rationale and design of" "the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. J Cardiovasc Med (Hagerstown). 2006 Jan;7(1):29–38."